Previous close | 378.00 |
Open | N/A |
Bid | 355.00 |
Ask | 365.00 |
Strike | 1,200.00 |
Expiry date | 2025-12-19 |
Day's range | 378.00 - 378.00 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing Phase 1/2 CHORD trial is currently enrolling infants and children in the U.S., UK and Spain TARRYTOWN, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) wi
TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Tuesday, May 14, 2024Jefferies Global Healthcare Conference at 8:30 a.m. ET on Wednesday, June 5, 2024Goldman Sachs 45th Annual Global Healthcare Conference at 8:00 a.m. ET on Tuesday, June 11, 2024 The sessions may be accessed from the "Investors & Media" page of Regeneron's website
In this article, we discuss the 23 most profitable stocks of the last 12 months. If you want to skip our detailed analysis of these stocks, go directly to 5 Most Profitable Stocks of the Last 12 Months. The United States stock market has come a long way since the turn of the millennium more […]